Sun Pharma gets USFDA nod for cancer drug

Sun Pharma gets USFDA nod for cancer drug
It was informed by the leading pharmaceutical company, Sun Pharmaceutical Industries Ltd., that it has received a nod from the US health regulator in relation to the introduction of the docetaxel injection in the American market.

Docetaxel is a drug used during the cancer treatment and will be brought in the US market in strengths of 20 mg/vial and 80 mg/vial. It is a specialized product used for treating lung cancer, metastatic breast cancer and harmone refractory metastic prostate cancer.

The subsidiary of the company, Sun Pharmaceutical Advanced Research Company is the one which has got US Food and Drug Administration approval for the drug, as informed by Sun Pharmaceutical.

Sun Pharmaceutical, often known just as Sun Pharma, makes many generic and brand name drugs that are distributed in the United States, Europe, and Asia and worldwide. It is India's biggest pharma company by market valuation of approx USD 8 billion and annual revenues of USD 950 million.

The company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopaedics and ophthalmology. It has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.

Read more about: sun pharmaceutical, nse, bse, pharma
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?